Chimeric-Antigen Receptor (CAR) T-Cell Therapy Using Multiple CARs and Cell Marker Profiling in High Risk and Relapsed/ Refractory B-Lineage Acute Lymphoblastic Leukaemia
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood
- Sponsor
- National University Hospital, Singapore
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Proportion of participant who are flow cytometry minimal residual disease (MRD) negative at the end of 1 month after CAR T-cell infusion.
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).
Detailed Description
Patients will receive CART-cells with one or more specificities according to the phenotypic profile of the leukemic cells in each individual patient. This will allow targeting the entire leukemia cell population to induce deeper and more durable remissions. Although it would be possible to administer CART-cells targeting all possible antigens to all patients, this indiscriminate approach would increase the CAR T-cell dose and hence, the risk of toxicity in patients that could be effectively treated with a lower, less toxic, CAR T-cell dose. Moreover, the cost of the procedure increases proportionally with the number of CAR T-cells used, limiting our capacity to enrol other patients. Reducing the number of CART-cells below the dose that we set, will inevitably increase the risk of treatment failure, according to the literature and our own experience.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Fulfil the Diagnosis/ Disease define as:
- •Relapsed B-cell acute lymphoblastic leukaemia/ lymphoma as defined by:
- •Bone marrow disease = or \> 0.01% by MRD as determined by flow cytometry Or CNS disease as defined as \> 5 WBCs in CSF by morphology, or flow cytometric or molecular evidence of blasts or biopsy proven recurrence in the eye or brain.
- •Or Extramedullary relapse as defined by morphological evidence of blasts in the testis or any other extramedullary sites
- •Induction failure as defined by Day 33/ End of induction:
- •MRD ≥ 1% by flow cytometry on the Ma-Spore ALL 2020 protocol Or Failure to achieve morphological remission defined as \> 5% blasts after standard induction chemotherapy
- •Refractory disease as defined by:
- •MRD ≥ 0.01% by flow cytometry or molecular methods during 2 or more timepoints after induction therapy
- •Any high risk features including :
- •BCR-ABL1, BCR-ABL1-like, - ABL1-r, PDGFRB-r, TCF3-HLF, MLL-r, hypodiploid ALL (\< 45 chromosomes), p53 pathogenic mutation as defined by RNA Seq or other molecular methods.
Exclusion Criteria
- •Failure to meet any of the inclusion criteria.
- •Patients who test positive on urine pregnancy testing and are pregnant or are lactating
- •Concomitant genetic syndromes associated with BM failure states, such as Fanconi anaemia, Kostmann syndrome, Schwachman syndrome, or any other BM failure syndrome with the exception of Down syndrome
- •Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and no evidence of active disease
- •Active or latent hepatitis B or active hepatitis C within 8 weeks of screening, or any uncontrolled infection at screening
- •Positive HIV test within 8 weeks of screening
- •Grade 2 to 4 acute graft-vs-host disease (GVHD) or extensive chronic GVHD
- •Received an investigational medicinal product within 30 days of screening
- •Persistent disease or relapse after other forms of CAR-T cell therapy.
Outcomes
Primary Outcomes
Proportion of participant who are flow cytometry minimal residual disease (MRD) negative at the end of 1 month after CAR T-cell infusion.
Time Frame: 30 days
MRD levels will be determined by flow cytometry, The target sensitivity of flow MRD is \<0.01% when available.
Secondary Outcomes
- Proportion of participant who are minimal residual disease (MRD) negative with molecular base assay at the end of 1 month after CAR T-cell infusion.(30 days)
- Proportion of patient who shows CAR T-cell persistence and presence of B-cell aplasia by immunophenotyping using flow cytometry in bone marrow, peripheral blood and CSF samples at multiple study time points following CAR T cell infusion(1 month to 5 years)